Efficacy of radiotherapy in normalizing serum IGF-I, acid-labile subunit (ALS) and IGFBP-3 levels in acromegaly by P. Epaminonda et al.
Clinical Endocrinology (2001) 55, 183–189
Efficacy of radiotherapy in normalizing serum IGF-I,
acid-labile subunit (ALS) and IGFBP-3 levels in
acromegaly
Paolo Epaminonda, Silvia Porretti, Vincenzo
Cappiello, Paolo Beck-Peccoz, Giovanni Faglia and
Maura Arosio
Institute of Endocrine Sciences, University of Milano,
Ospedale Maggiore IRCCS, Milano, Italy
(Received 17 November 2000; returned for revision 10 December
2000; finally revised 16 October 2000; accepted 23 February
2001)
Summary
OBJECTIVE Radiotherapy (RT) has been used for
many years in order to complete the cure of
unsuccessfully operated acromegalic patients. Sev-
eral studies have shown its efficacy in normalizing
GH levels, while reports about IGF-I normalization are
conflicting. Moreover, data regarding other markers
of disease activity, such as IGFBP-3 and acid-labile
subunit (ALS), i.e. the other two components of the
circulating 150 kDa complex, are lacking.
DESIGN Retrospective study.
PATIENTS AND MEASUREMENTS Sixty-seven acro-
megalic patients (20 males and 47 females, aged
40 ^ 6 years) who underwent postoperative RT (in
fractionated doses for a total of 40–75 Gy) were
followed-up for 11 ^ 6 years (range: 1–26 years,
median: 10 years). Serum GH and IGF-I levels off
medical therapy were measured in all patients; ALS
and IGFBP-3 were measured in 11 patients with
normalization of IGF-I concentrations. Computed
tomography or nuclear magnetic resonance imaging
periodically assessed possible development of pitui-
tary deficiency along with imaging of the hypotha-
lamic-pituitary region.
RESULTS Forty-one out of 67 patients (58%)
achieved GH levels , 2·5 mg/l by 1–15 years after
RT (mean 8 ^ 6) and 37/67 patients (55%) had normal
or low IGF-I levels 1–26 years after RT (mean:
12 ^ 6), a normalization of both parameters being
seen in 37 patients. GH , 2·5 mg/l and normal IGF-I
levels were achieved in 17/26 (65%) patients followed-
up for at least 15 years. ALS and IGFBP-3 concentra-
tions paralleled IGF-I levels in all patients studied.
With respect to secondary pituitary insufficiency,
acquired ACTH deficiency was found in 25 patients,
TSH deficiency in 20, gonadotropin deficiency in 23
and GH deficiency in seven. In total, two cases of
meningioma and one pineal tumour, possibly related
to RT, were seen 9–22 years after RT.
CONCLUSIONS RT is an effective, although slow-
acting, therapeutic tool for acromegaly, with ‘safe’ GH
levels and normal IGF-I concentrations being
achieved in 65% of patients after 15 years. IGF-I
levels normalize more slowly than GH levels. Radio-
therapy is able to normalize the concentration of all
three components of the circulating 150 kDa com-
plex. Checks for loss of pituitary function and
appearance of second brain tumours must be carried
out life-long.
Conventional external radiotherapy has been used for many
years in the treatment of acromegaly. In fact, most reports show
that, after 2 years, GH concentrations decrease by approxi-
mately 50% from baseline and, after 5 years, by approximately
75%, with an overall rate of success of 50–90% at 10–15 years
(Eastman et al., 1992; Goffman et al., 1992; Jaffe, 1999). If the
actual more restrictive criteria to define the control of
acromegalic disease are taken into account, i.e. GH serum
levels , 1 mg/l after oral glucose load, and mean baseline
GH , 2·5 mg/l (‘safe GH levels’) (Bates et al., 1993; Giustina
et al. 2000), the success rate in controlling GH hypersecretion is
probably lower, accounting for 20–30% (Gorden et al., 1987;
Thalassinos et al., 1998). Moreover, serum IGF-I levels are
considered an important marker of disease activity in acrome-
galy, with their normalization being an inalienable part of the
concept of cure of acromegaly (Frohman, 1996). Surprisingly, it
was recently claimed that, at variance with GH, IGF-I serum
levels do not normalize in acromegalic patients treated with
radiotherapy, thus suggesting a dissociated effect on GH and
IGF-I levels (Barkan et al., 1997). Nothing is known about
radiotherapy effects on the other components of ternary
complex, i.e. acid-labile subunit (ALS) and IGFBP-3, the levels
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of which are good additive parameters of active acromegaly
(Grinspoon et al., 1995; Baxter, 1997). To further study this
issue, we have retrospectively re-evaluated the effects of
conventional radiotherapy on GH and IGF-I levels in all
irradiated acromegalic patients seen at our Institute who were
followed-up for a minimum of 1 year. ALS and IGFBP-3 levels
were also measured in a small subgroup of patients who
normalized IGF-I concentrations. Finally, because RT fre-
quently induces hypopituitarism and, more rarely, second brain
tumours, side-effects were evaluated.
Patients and methods
Patients
We included in the present study 67 patients (47 females and
20 males, mean age at the time of radiotherapy: 40·5 ^ 6 years)
out of 80 who were diagnosed and/or treated in our Institute and
irradiated from 1969 to 1996. Ten patients were excluded
because they were followed for a period of time shorter than
1 year, and three because they lacked IGF-I measurements.
Sixty-two patients underwent previous unsuccessful pituitary
surgery (61 by a transnasosphenoidal and one by a transfrontal
approach), while five patients had radiotherapy as the primary
treatment. Seventy percent of patients were irradiated at our
Hospital with a three-field technique, using a 60Co source, while
no information could be obtained on the technique used for the
remaining patients who were treated elsewhere. The mean dose
delivered was 53·6 Gy (range: 40–75), fractionated in 30–35
sessions (1·5–1·8 Gy for each application). Three patients
received two cycles of radiotherapy 4–8 years apart. After
radiotherapy, 11 patients were treated with somatostatin
analogues alone, 24 patients with dopaminergic drugs and six
with both. However, all the data reported in the present paper
were obtained during adequate withdrawal of medical therapy
(1 month for the 12 patients treated with octreotide s.c. and three
months for the five patients treated with lanreotide 30 mg i.m.).
Protocol
Before radiotherapy, each patient was evaluated for serum GH
levels (mean of at least three serial serum samples) and antero-
pituitary function (basal PRL, TSH, LH, FSH, cortisol, thyroid
hormones, testosterone in males and 17-beta oestradiol in
females, TSH response to TRH, gonadotropin response to
GnRH and cortisol response to insulin hypoglycemia or low
dose, 1 mg ACTH test). Posterior pituitary function was
evaluated on clinical grounds. IGF-I levels were available
before therapy in 28 patients. The follow-up after radiotherapy
ranged from 1 to 26 years (12 ^ 6 years, median: 10 years).
Serum GH was measured at each visit, with IGF-I starting from
1986. Only hormonal assessment carried out off medical therapy
were considered. Data were analysed at 1, 2, 3, 4, 5, 10 (taking
into account the nearest data obtained at ^ 6 months for the first
5 years and between 8 and 12 years for 10 years), 13–15 and
more than 15 years after the execution of radiotherapy cycles.
Complete pituitary function studies were performed approxi-
mately every 3 years. ALS and IGFBP-3 were measured in 11
patients with apparent normalization of IGF-I concentrations.
The samples were all taken in the fasting state.
Hormone assays
Serum GH values were measured over the years by different
assays: a double antibody radioimmunoassay (RIA), using
anti-hGH supplied by NIH and 125I hGH supplied by CEA-
CEN-Sorin (Saluggia, Italy) until 1975; HGH RIA Kit, Dow
Lepetit (Milano, Italy) until 1982; HGH RIA LISOPHASE,
Sclavo (Milano, Italy) until 1992 and a fluoroimmunoassay
(AutoDELFIATM hGH, Wallac Oy, Turku, Finland) in the
most recent years. This latter assay has a detectability level of
0·01 mg/l, and intra- and interassay coefficients of variation of
4·1% and 9%, respectively. The three oldest kits utilized
standards calibrated against the WHO first IRP HGH-MRC 66/
217 (1 mg/l  2 mIU/l), while AutoDELFIA uses standards
calibrated against NIH 1RP 80/505 (1 mg/l  2·6 mIU/l). The
last GH determination for each patient was performed by
AutoDELFIA. For the purposes of this study, all GH data were
treated similarly. Data are expressed in mg/l.
Serum IGF-I concentrations were measured by commercial
RIA kits: from 1986 to 1996, by Incstar (Stillwater, MN, USA)
after removal of binding proteins by acidification and filtration
on ODS C18 cartridges, with intra- and interassays coefficients
of variation of 15 and 16%, respectively; afterwards by
Mediagnost (Tu¨bingen, Germany) which succeeds in obtaining
separation between IGF-BP and IGF-I by acidification in IGF-
II excess. The last assay has a detectability level of 0·02 ng/ml,
and intra- and interassay coefficients of variation of 3·2 and
8·9%, respectively. In our hands, the results obtained with the
two methods have a coefficient of correlation of 0·97. For both
assays, data were compared with an appropriate age-adjusted
range obtained in 100 healthy adult controls, ranging from 20
to 61 nmol/l at 18 years to 6–26 nmol/l at 70 years. For each
patient, the last IGF-I measurement was performed by
Mediagnost.
Total ALS was measured by means of specific two-site
sandwich enzyme-linked immunosorbent assay, using anti ALS
antibodies raised against synthetic amino-terminal and carboxy-
terminal ALS peptides, reagents and tracer provided by
Diagnostic System Laboratories (Webster, TX, USA). All
samples were pretreated in order to dissociate the complexed
ALS and enhance ALS immunoreactivity. The sensitivity of the
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assay was 400 ng/ml; the intra-assay and interassay coefficients
of variation were 5·5 and 7·2%, respectively. Recovery of the
human serum-derived glycosylated ALS was 75% for the lowest
concentration added (1 mg) and 95% for the highest concentra-
tion added (60 mg). The normal range, determined in 100 healthy
adult subjects, is 216–350 nmol/l, without any significant age-
related modifications in adult life (Barreca et al., 1999).
IGFBP-3 was measured by immunometric assay, using
reagents and tracer provided by Diagnostic System Labora-
tories (Webster, TX, USA) as previously described (Barreca et
al., 1995). The sensitivity of the assay is 1·5 ng/ml; the intra-
and interassay coefficients of variation are 3·25 and 5·6%,
respectively.
Normal levels, determined in 100 healthy adult subjects, range
from 71 to 140 nmol/l at 18 years to 42–126 nmol/l at 70 years.
Statistical analysis
All data were expressed as the mean ^ SD unless otherwise
stated. Relationship between parameters was determined by
Pearson’s correlation. P , 0·05 was considered statistically
significant.
Results
Pre-radiotherapy assessment
Before radiotherapy, basal mean serum GH levels were
20·2 ^ 27 mg/l, ranging from 3·2 to 190 mg/l. Eight patients
were hyperprolactinaemic (mean: 37·6 mg/l; range: 24–64), six
patients were hypothyroid, four hypoadrenal and one hypogo-
nadal. Mean IGF-I levels, measured in 28 patients, were
110·8 ^ 48 nmol/l, ranging from 47 to 243 nmol/l (all IGF-I
levels were high if compared with age-matched controls).
Overall effects of radiotherapy on GH levels
GH concentrations decreased to below 2·5 mg/l in 41 out of 67
patients (61%) after a mean of 8 ^ 6 years. Radiotherapy
preceded the achievement of low GH levels of a period ranging
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Fig. 1 Percentage decrease of GH and IGF-I levels (mean ^ SE) in
26 acromegalic patients.
Fig. 2 Coronal magnetic resonance imaging view of a possibly
radiotherapy-induced voluminous meningioma in an acromegalic
patient (histology: meningotheliomatous meningioma).
Table 1 Percentage of patients who normalized GH and IGF-I levels in relationship with pretreatment values and time elapsed from radiotherapy
Time Percentage of patients Baseline GH levels (mg/l) Percentage of patients Baseline IGF-I levels (nmol/l)
0–3 years 22 5·9 ^ 2 12 51 ^ 21
3–4 years 9 7·7 ^ 4 0 –
4–5 years 6 9·1 ^ 5 12 93 ^ 25
5–10 years 12 24·6 ^ 25 31 92·4 ^ 39
. 10 years 12 19·3 ^ 11 0 –
Never 39 43·0 ^ 49 45 132 ^ 50
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from 1 to 20 years, being longer than 5 years in 40% of
patients. The delay in the achievement of these GH levels was
largely dependent on GH concentration at baseline (Table 1).
Overall effects of radiotherapy on IGF-I, ALS and
IGFBP-3 levels
Serum IGF-I normalized in 37/67 patients after 12 ^ 6 years
(range: 1–26 years). Among these patients, 55% normalized
IGF-I concentrations after more than 5 years and one-third
after more than 10 years.
We did not observe any patient with normal IGF-I values
and GH levels . 2·5 mg/l, while four patients who achieved
‘safe’ serum GH levels did not normalize IGF-I levels. Ten
patients showed IGF-I levels below the third percentile for age
(mean time at diagnosis: 15 ^ 6 years post RT). In seven of
these patients, a deficiency of GH secretion was confirmed by
an absent GH increase after an insulin tolerance test (ITT) or
combined GHRH-arginine administration. Serum ALS and
IGFBP-3 measured in 11 acromegalics who achieved normal
IGF-I concentrations and GH levels below 2·5 mg/l were also
normalized. In these patients, ALS levels ranged from 160 to
341 nmol/l (mean: 240 ^ 10), and IGFBP-3 from 48 to
127 nmol/l (mean: 85 ^ 1·7). In the three patients with low
IGF-I levels, ALS concentrations were low, while IGFBP-3
concentrations were normal in one patient and in the low-
normal range in two.
Long-term efficacy of radiotherapy
Among the 26 patients followed for 15 or more years, 17
(65%) achieved safe GH and normal IGF-I levels. Nine
patients who did not normalize hormonal parameters, even
after 15 or more years, showed quite stable GH and IGF-I
levels in the last years.
Comparison between effects on GH and IGF-I levels
Twenty-six patients had IGF-I measured before radiotherapy.
The decrease of GH and IGF-I levels showed a significant
correlation (r  0·951, P , 0·001). However, while mean GH
serum levels showed a 39% decrease in the first year after
radiotherapy (from 14·7 mg/l to 9·1 mg/l), halved at 2 years
and were diminished by 95% at 10 years, IGF-I levels showed
a slower decrease over the years. In fact, only a 5% reduction
was seen in the first year, a 35% reduction during the second
year, halved at fifth year; and were reduced by 75% 10 years
after radiotherapy (Fig. 1).
Both serum GH and IGF-I levels before therapy appear to be
good predictors of efficacy of radiotherapy: in fact, basal GH
and IGF-I levels of patients who achieved ‘safe’ GH levels
were significantly lower than the basal levels of the patients
who did not (12 vs. 42 mg/l and 86·5 ^ 37 vs.
143·1 ^ 42 nmol/l, for GH and IGF-I, respectively).
Other pituitary function
Before RT, eight patients were hyperprolactinaemic and 59
normoprolactinaemic. Half of the hyperprolactinaemic patients
normalized PRL concentrations 2–5 years after RT, but only
in one case was this finding associated with the achievement of
safe GH and IGF-I levels. Before radiotherapy, six patients
were hypothyroid, four hypoadrenal and one hypogonadal.
After radiotherapy, one or more anterior pituitary deficiencies
occurred in 60% of patients. Radiotherapy-induced ACTH
deficiency occurred in 25 patients (36%) (mean time at
diagnosis: 6 ^ 6 years post RT, range: 1–20 years), TSH
deficiency in 20 (30%) (mean time at diagnosis: 4 ^ 5 years
post RT, range: 1–18 years), gonadotropin deficiency in 23
(34%) (mean time at diagnosis: 7 ^ 5 years following radio-
therapy; range: 1–18 years). (Table 2). It is of note that all six
patients who received doses higher than 55 Gy developed
panhypopituitarism.
Radiotherapy-induced tumours
Three tumours involving brain-areas near to the field of
irradiation were observed 9–22 years after radiotherapy: two
meningiomas and one neoplasm of unknown histology. The
two meningiomas were 1 and 4 cm, respectively (Fig. 2), were
completely asymptomatic and were diagnosed only by a NMR
imaging routine follow-up. At the time of diagnosis, patients
showed normal IGF-I and very low GH levels. Both patients
had received one cycle of radiotherapy at the dose of 54 Gy.
They underwent successful surgery, and histology confirmed
that the masses were meningiomas. The third patient showed
neurological symptoms and signs in 1983, 13 years after the
first and 9 years after a second cycle of radiotherapy (total
dose approximately 72 Gy). A computed tomography scan
showed a pineal mass that caused hydrocephalus. Treated by
radiotherapy the patient was then lost at follow-up and died
Table 2 Pituitary deficiency in irradiated patients
Pituitary
deficiency
No. of
patients (%)
Mean time
at diagnosis (years)
ACTH 25 (37%) 6 ^ 6
TSH 20 (30%) 4 ^ 5
LH/FSH 23 (34%) 7 ^ 5
GH 7 (10%) 15 ^ 6
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3 years later. When he died, normalization of GH and IGF-I
levels had not occurred. No cases of optic nerve damage or
cranial nerve palsies were observed.
Discussion
The present data show that radiotherapy is able to normalize
IGF-I levels and the other two components of the circulating
ternary complex, IGFBP-3 and ALS, besides GH. Our rate of
GH percent fall is superimposable to that reported previously
(Gorden et al., 1987; Jaffe, 1999). We observed IGF-I
normalization in 55% of the patients. This finding is lower
than that described by Ciccarelli et al. (1993) with a
normalization of IGF-I levels in 68% (follow-up: 2–4 years)
and by Biermasz et al. (2000) who observed 84% of patients
with normal IGF-I 15 years after RT. Our data are indeed more
similar to those of Af Trampe et al. (1991) who report
normalization of IGF-I levels in 57% out of 40 patients 3–
12 years postirradiation, and to those of Powell et al. (2000)
who observed normal IGF-I levels in approximately 40% of
patients after a mean of 5·2 years. These studies report a
slower decrease in IGF-I levels in respect to GH, with the
earliest significant decrease of IGF-I mean levels being
observed after 2 years, a year later than that observed for
GH (Ciccarelli et al., 1993). In contrast, an almost complete
ineffectiveness of pituitary irradiation to normalize serum IGF-
I was claimed by Barkan et al. (1997) and Thalassinos et al.
(1998), with normalization of IGF-I in 5% after a mean of
7 years and 28% after 10 years, respectively. Although it is
difficult to find a fully satisfactory explanation for these
discrepant data, it should be stressed that both length of follow-
up and basal GH levels are of paramount importance in
evaluating the results of radiotherapy. In both of these studies,
the average duration of follow-up was 3–4 years shorter than
ours. In addition, most of the patients studied by Thalassinos
et al. received radiotherapy without previous surgery and had
pretreatment GH levels higher than the patients of the present
study. Four patients from the present series presented elevated
IGF-I levels with low mean fasting GH levels (below 2 and
even 1 mg/l). Similar observations have been reported by
others (Powell et al. 2000), suggesting that radiotherapy may
induce an abnormal pattern of GH release and pulsatility, with
a greater ‘nonpulsatile’ release of GH in irradiated patients
with respect to normal controls (Jaffe, 1999; Peacey & Shalet,
1999). This abnormal release of GH would induce a continued
stimulation of IGF-I.
IGF-I is for the most part bound to a circulating complex of
150 kDa constituted by a specific IGF-binding protein
(IGFBP-3), and by an ALS besides IGF-peptide. These two
proteins are GH-dependent, and their use as markers of
integrated GH secretion is well established. They offer the
advantage over IGF-I of a simpler measurement, being
unaffected by IGFBPs which interfere in IGF-I assays and,
as far as ALS is concerned, of a minor age-dependency.
Approximately 90% of untreated patients show high ALS
concentrations (Hoffman et al., 1997; Arosio et al., 2001) and
elevated IGFBP-3 concentrations of approximately 75%
(Arosio et al., 2001; Thissen et al., 1996).
Successful surgery has been shown to normalize ALS and
IGFBP-3 levels. The absence of elevated levels of ALS or
IGFBP-3 in the subgroup of patients with normal IGF-I is a
further demonstration that radiotherapy is indeed able to cure
acromegaly. Further studies will be necessary to understand
whether the decreases in the levels of ALS/BP3 more closely
mirrors decreases in GH or IGF-I. In addition ALS, but not
IGFBP-3, was shown to be an index as sensitive as IGF-I in
detecting a growth hormone deficiency. In our study, a highly
positive correlation between basal and final GH values was
found. This is concordant with previous findings of a higher
frequency and earlier appearance of ‘normal’ GH levels after
RT in patients with lower pretreatment GH levels (Littley et al.,
1990; Ciccarelli et al., 1993; Jaffe, 1999). This observation
may be extended to basal IGF-I levels, which can be
considered, together with GH levels, as an important predictive
factor of RT efficacy. This stresses the importance of
therapeutical tools, such as surgery, which should be
performed before radiotherapeutical applications to improve
its efficacy, and definitively rejects RT as a primary
therapeutic choice. Progressive hypopituitarism is a well-
known sequela of radiotherapy. In this regard, our data are
fully concordant with those reported in the literature (Af
Trampe et al., 1991; Ciccarelli et al., 1993; Eastman et al.,
1992; Thalassinos et al., 1998). An important aspect is that
10% of patients who showed GH hypersecretion became GH
deficient after radiotherapy. Because GH deficiency is
characterized by an increase in morbidity and mortality that
is not less than acromegaly, a definitive diagnosis (by means of
IGF-I evaluation and, if necessary, stimulation testing) must be
performed. If GH deficiency is confirmed, an adequate
treatment with rhGH has to be started. Biermasz et al.
(2000) reported a higher percentage of GH deficiency (36%)
using ITT. This testing may overestimate the real prevalence of
GH deficiency because abnormal GH responses to ITT are
described in active acromegaly.
In addition, the possibility of radiotherapy-induced neopla-
sia is well known. We reported three cases of encephalic
tumours located near the irradiated hypothalamic-pituitary
region found after 10–20 years. These are likely due to
radiotherapy. This fact indicates that the risk of radiotherapy-
induced neoplasia is extremely low but still present, even in the
modern mega-voltage era (Parker, 1990; Ahmed et al., 1997).
The percentage of radiotherapy-induced malignancies in our
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study is high when compared with the results reported by
Brada et al. (1992) (1·9% at 20 years) and by other studies
(Tsang et al., 1993; Barcelo` et al., 1998) regarding the effects
of radiotherapy in secreting and non-secreting pituitary
adenomas. It is tempting to speculate that increased IGF-I
levels may act as a possible carcinogenic factor (Khandwala
et al. 2000), and may increase the risk of a second tumour in
irradiated acromegalic patients in contrast to patients harbour-
ing different kinds of pituitary tumours. It is important to note
that two out of the three cases of secondary brain tumours were
clinically silent, and have been detected after a close
surveillance by nuclear magnetic resonance imaging and a
long follow-up. This fact stresses once again the importance of
careful life-long follow-up in irradiated patients even if they
are asymptomatic and cured.
In conclusion, radiotherapy still remains an effective tool to
treat acromegaly. However, using modern, more stringent
criteria, its efficacy does not appear to be as high as previously
reported. It may cause serious side-effects and requires life-
long follow-up of patients.
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